

DAFTAR PUSTAKA

1. Haigh, KA, Twabi, HH, Boloko, L, Namale, PE, Lutje, V, Nevitt, S & Davies, G 2024, 'Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysis', *EClinicalMedicine*, vol. 77, 102857. <https://doi.org/10.1016/j.eclinm.2024.102857>
2. Kementerian Kesehatan Republik Indonesia. Annual National TB Program 2022. Jakarta; 2022. 1–57 p.
3. Dirjen P2P. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Kemenkes 2022; 1–147. Dari: <https://tbindonesia.or.id/wpcontent/uploads/2023/09/Laporan-Tahunan-Program-TBC-2022>.
4. WHO. (2025). Global Tuberculosis Report 2025, Geneva.
5. TRUNCATE-TB Trial Team (Accepted/In press). Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial. *The Lancet Infectious Diseases*, 25(10), 1084-1096. [https://doi.org/10.1016/S1473-3099\(25\)00151-3](https://doi.org/10.1016/S1473-3099(25)00151-3).
6. Adane T, Melku M, Ayalew G, Bewket G, Aynalem M, Getawa S. Accuracy of monocyte to lymphocyte ratio for tuberculosis diagnosis and its role in monitoring anti-tuberculosis treatment: Systematic review and meta-analysis. *Medicine (Baltimore)*. 2022 Nov 4;101(44):e31539. doi: 10.1097/MD.00000000000031539. PMID: 36343023; PMCID: PMC9646665.
7. Wang, W., Wang, L. F., Liu, Y. Y., Yang, F., Zhu, L., & Zhang, X. H. (2019). Value of the ratio of monocytes to lymphocytes for monitoring tuberculosis therapy. *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2019(1), 3270393
8. Khan, M. M., Basit, A., Khan, M. H., & Sabahat, S. Sensitivity and Specificity of Monocyte-Lymphocyte Ratio to Predict Active Tuberculosis. *MLR*, 15, 12-40.
9. Handoko, B., Arliny, Y., Priyanto, H., Andayani, N., & Yanifitri, D.B. (2025). Analysis of Monocyte to Lymphocyte Ratio and Clinical Symptoms of Clinically Confirmed Pulmonary Tuberculosis New Case Patients Before Treatment and After Intensive Phase. *Jurnal Respirologi Indonesia*.
10. Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. *Nat Rev Microbiol*. 2022 Nov;20(11):685-701. doi: 10.1038/s41579-022-00731-y. Epub 2022 Apr 27. PMID: 35478222; PMCID: PMC9045034.

11. Cheng P, Wang L, Gong W. Cellular Immunity of Patients with Tuberculosis Combined with Diabetes. *J Immunol Res*. 2022;2022:6837745. Published 2022 Jun 1. doi :10.1155/2022/6837745.
12. Kumar M, Virmani T, Kumar G, Deshmukh R, Sharma A, Duarte S, Brandão P, Fonte P. Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies. *Pharmaceuticals* (Basel). 2023 Sep 26;16(10):1360. doi: 10.3390/ph16101360. PMID: 37895831; PMCID: PMC10609727.
13. Perhimpunan Dokter Paru Indonesia. Tuberculosis pedoman diagnosis dan penatalaksanaan di indonesia. Edisi 2. Perhimpunan Dokter Paru Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI); 2021. 1–89 p.
14. Motta, I., Boeree, M., Chesov, D., Dheda, K., Günther, G., Horsburgh Jr, C. R., & Guglielmetti, L. (2024). Recent advances in the treatment of tuberculosis. *Clinical Microbiology and Infection*, 30(9), 1107-1114.
15. Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. *Int J Mol Sci*. 2023 Mar 8;24(6):5202. doi: 10.3390/ijms24065202. PMID: 36982277; PMCID: PMC10049048.
16. WHO. (2022). WHO operational handbook on tuberculosis. Module 4: treatment - drug-susceptible tuberculosis treatment.
17. Silva DR, Mello FCQ, Migliori GB. Shortened tuberculosis treatment regimens: what is new? *J Bras Pneumol*. 2020 Mar 23;46(2):e20200009. doi: 10.36416/1806-3756/e20200009. PMID: 32215450; PMCID: PMC7462706.
18. Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. *Open Forum Infect Dis*. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. PMID: 38444824; PMCID: PMC10914527.
19. Velásquez, G. E., Brooks, M. B., Coit, J. M., Pertinez, H., Vargas Vásquez, D., Sánchez Garavito, E., ... & Mitnick, C. D. (2018). Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial. *American journal of respiratory and critical care medicine*, 198(5), 657-666.
20. Kim HJ, Lee YJ, Song MJ, Kwon BS, Kim YW, Lim SY, Lee YJ, Park JS, Cho YJ, Lee CT, Lee JH. Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis. *Sci Rep*. 2023 Jul 12;13(1):11275. doi: 10.1038/s41598-023-38394-1. PMID: 37438379; PMCID: PMC10338469.

21. Gill CM, Dolan L, Piggott LM, McLaughlin AM. New developments in tuberculosis diagnosis and treatment. *Breathe (Sheff)*. 2022 Mar;18(1):210149. doi: 10.1183/20734735.0149-2021. Epub 2021 Mar 8. PMID: 35284018; PMCID: PMC8908854.
22. Ramappa, V., & Aithal, G. P. (2013). Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. *Journal of clinical and experimental hepatology*, 3(1), 37-49.)
23. Kass, J. S., & Shandera, W. X. (2010). Nervous system effects of antituberculosis therapy. *CNS drugs*, 24(8), 655-667.
24. Sundas, A., Ashraf, S., & Saeed, R. (2025). Hyperuricemia in Tuberculosis Patients Treated with Pyrazinamide. *Journal of Health, Wellness, and Community Research*, e105-e105.
25. Sen, S., Mandal, S., Banerjee, M., Gk, R., Saxena, A., Aalok, S. P., & Saxena, R. (2022, August). Ethambutol-induced optic neuropathy: Functional and structural changes in the retina and optic nerve. In *Seminars in Ophthalmology* (Vol. 37, No. 6, pp. 730-
26. Aggarwal, R., Sethi, P., Duvesh, R. K., Sethi, H. S., Naik, M., & Rai, H. K. (2021). Ocular toxicity of Anti-Tubercular drugs. *Delhi Journal of Ophthalmology*, 31(4), 35-38.
27. Suryana K, Dharmesti NWW, Rai IBN. High Pretreatment Level of Neutrophil to Lymphocyte Ratio, Monocyte to Lymphocyte Ratio and Other Factors Associated with Delayed Sputum Conversion in Patients with Pulmonary Tuberculosis. *Infect Drug Resist*. 2022 Sep 15;15:5455-5462. doi: 10.2147/IDR.S380166. PMID: 36131811; PMCID: PMC9484577.
28. Omair, M., Baig, M. S., Farooqui, W. A., Kousar, S., Noori, M. Y., Zeehan, N., & Mehmood, M. (2024). Relationship of neutrophil lymphocyte ratio, monocyte lymphocyte ratio and neutrophil monocyte ratio with treatment response in pulmonary tuberculosis patients during intensive phase treatment. *BMC Infectious Diseases*, 24(1), 1-7.
29. Choudhary RK, Wall KM, Njuguna I, Pavlinac PB, LaCourse SM, Otieno V, Gatimu J, Stern J, Maleche-Obimbo E, Wamalwa D, John-Stewart G, Cranmer LM. Monocyte-to-Lymphocyte Ratio Is Associated With Tuberculosis Disease and Declines With Anti-TB Treatment in HIV-Infected Children. *J Acquir Immune Defic Syndr*. 2019 Feb 1;80(2):174-181. doi: 10.1097/QAI.0000000000001893. PMID: 30399036; PMCID: PMC6448767.
30. Zelmer A, Stockdale L, Prabowo SA, Cia F, Spink N, Gibb M, Eddaoudi A, Fletcher HA. High monocyte to lymphocyte ratio is associated with impaired protection after subcutaneous administration of BCG in a mouse model of tuberculosis. *F1000Res*. 2018 Mar 8;7:296. doi: 10.12688/f1000research.14239.2. PMID: 30026926; PMCID: PMC6039926.

31. Fu S, Wu D, Jiang W, Li J, Long J, Jia C, Zhou T. Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. *Front Pharmacol*. 2020 Jan 30;10:1667. doi: 10.3389/fphar.2019.01667. PMID: 32082163; PMCID: PMC7002317.
32. Liu Q, Guo D, Yu M, Tang D, Zhang Y, Luo M, He J. Clinical characteristics and risk factors for antituberculosis drug-induced hypersensitivity. *Br J Clin Pharmacol*. 2025 Jan;91(1):134-142. doi: 10.1111/bcp.16228. Epub 2024 Sep 8. PMID: 39245967.
33. Buttle TS, Hummerstone CY, Billahalli T, Ward RJB, Barnes KE, et al. (2021) The monocyte-to-lymphocyte ratio: Sex-specific differences in the tuberculosis disease spectrum, diagnostic indices and defining normal ranges. *PLOS ONE* 16(8): e0247745. <https://doi.org/10.1371/journal.pone.0247745>.
34. Analysis of Monocyte to Lymphocyte Ratio and Clinical Symptoms of Clinically Confirmed Pulmonary Tuberculosis New Case Patients Before Treatment and After Intensive Phase. (2025). *Jurnal Respirologi Indonesia*, 45(1), 55–60. <https://doi.org/10.36497/jri.v45i1.533>